Envveno Medical Corp (NVNO)

$4.96 -0.06 (-1.20%)
Market Cap 86.98M
Revenue (ttm) 0.00
Net Income (ttm) -21.82M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 188,400
Avg Vol 124,890
Day's Range N/A - N/A
Shares Out 17.54M
Stochastic %K 56%
Beta 0.93
Analysts Strong Sell
Price Target $12.50

Company Profile

enVVeno Medical Corporation, a clinical-stage medical device company, focuses on the development of bioprosthetic tissue-based solutions to enhance the standard of care in the treatment of venous disease. The company's lead product is the VenoValve, a replacement venous valve for the treatment of venous chronic venous insufficiency. Its VenoValve implanted into the femoral vein of the patient in an open surgical procedure via a 5-to-6-inch incision in the upper thigh. The company also develops e...

Industry: Medical Devices
Sector: Healthcare
Phone: 949 261 2900
Address:
70 Doppler, Irvine, United States
kmx_swing
kmx_swing Jul. 26 at 8:52 AM
$NVNO not sure how high it will go...but we will reach at minimum $8 because of warrants...then is the question how long it will take market to digest that those cashed $70M are in fact an excellent news..
0 · Reply
cohunter9
cohunter9 Jul. 26 at 2:57 AM
$NVNO min 4x profit, or lose it all.
1 · Reply
LifeisaMeme
LifeisaMeme Jul. 25 at 11:52 PM
$NVNO Yea im tired of stocks going up that make no money and good companies go down. Im so fucking tired of this bullshit. The SEC needs to do something about it but of course it will never happen.
0 · Reply
Icemanja
Icemanja Jul. 25 at 11:19 PM
$NVNO Maybe if they post bad new we'll go up? At this point i've seen it all. Not sure who Breman pissed off with deep pockets but they keep hammerring us no matter what!!
1 · Reply
Thorne321
Thorne321 Jul. 25 at 8:32 PM
$NVNO I’m coming to conclusion there to quite about this prone for a buyout . Why would they not advertise this or give it more publicity. So others can acquire at relatively lower price I guess ?
0 · Reply
Liverpool13
Liverpool13 Jul. 25 at 8:03 PM
$NVNO “…”the good news is that we are working here in Irvine on a device that we are waiting for FDA approval for people with much more severe disease, called the VenoValve, which is a prosthetic valve that implanted into the vein that restores normal flow. It’s a new valve in these legs that have very diseased valves. So that’s what we are waiting for from the FDA for approval of our device” -Dr Marc Glickman, CMO. Saturday Agenda, Newsmax (end of interview posted on news section of envveno website
0 · Reply
Liverpool13
Liverpool13 Jul. 25 at 7:57 PM
$NVNO not sure if this was posted yet but more interviews of the CMO are added to the news tab of the website and BINGO!….CMO plugs the device pending FDA approval! See the Saturday Newsmax video which should be the third overall video (2nd of the Newsmax ones). He plugs device in last 30 seconds of video interview. Video in the link is entitled: “Dr. Marc Glickman, Senior Vice President and Chief Medical Officer for enVVeno Medical, joins Newsmax’s Saturday Agenda to explain President Donald Trump’s health updates announced by the White House on Thursday.” https://envveno.com/in-the-news/
0 · Reply
LifeisaMeme
LifeisaMeme Jul. 25 at 7:39 PM
$NVNO Berman literally thinks retail is stupid. We aint selling buddy. Either you go bankrupt, or we all gain from this. Contact FDA Berman. OMG your Ivy league start acting like it.
0 · Reply
The_Giggly_Hyena
The_Giggly_Hyena Jul. 25 at 6:44 PM
$NVNO
1 · Reply
kmx_swing
kmx_swing Jul. 25 at 6:42 PM
$NVNO FDA hates Trump...that is why they have not approved yet...we need Palestian leaders to have chronic venous insufficiency and Obama in charge...then the approval is guaranteed yesterday 😉🫣
1 · Reply
Latest News on NVNO
enVVeno Medical Participates in the Virtual Investor "What's Your Story" Summer Spotlight On-Demand Conference

Jul 22, 2025, 8:45 AM EDT - 4 days ago

enVVeno Medical Participates in the Virtual Investor "What's Your Story" Summer Spotlight On-Demand Conference

Positive Interim 2-Year Data from enVVeno Medical's VenoValve Pivotal Study to be Presented Today at the Society for Vascular Surgery (SVS) 2025 Vascular Annual Meeting

Jun 6, 2025, 8:05 AM EDT - 7 weeks ago

Positive Interim 2-Year Data from enVVeno Medical's VenoValve Pivotal Study to be Presented Today at the Society for Vascular Surgery (SVS) 2025 Vascular Annual Meeting

enVVeno Medical Appoints Jennifer Bright as Chief Financial Officer

May 19, 2025, 8:05 AM EDT - 2 months ago

enVVeno Medical Appoints Jennifer Bright as Chief Financial Officer

Three-Year VenoValve(R) First-in-Human Trial Data Published in the Annals of Vascular Surgery

May 13, 2025, 8:45 AM EDT - 2 months ago

Three-Year VenoValve(R) First-in-Human Trial Data Published in the Annals of Vascular Surgery

enVVeno Medical Reports First Quarter 2025 Financial Results and Reiterates Progress Toward VenoValve FDA Decision Expected in 2H24

May 1, 2025, 8:05 AM EDT - 3 months ago

enVVeno Medical Reports First Quarter 2025 Financial Results and Reiterates Progress Toward VenoValve FDA Decision Expected in 2H24

VenoValve to be Featured During Presentation at the 47th Annual Charing Cross Symposium

Apr 23, 2025, 8:00 AM EDT - 3 months ago

VenoValve to be Featured During Presentation at the 47th Annual Charing Cross Symposium

enVVeno Medical to Participate in a Live Virtual Investor Closing Bell Segment

Apr 16, 2025, 8:30 AM EDT - 3 months ago

enVVeno Medical to Participate in a Live Virtual Investor Closing Bell Segment

The Impact of the VenoValve(R) on Patients with Primary and Secondary Chronic Venous Insufficiency (CVI) to be Presented at the Society for Clinical Vascular Surgery 52nd Annual Symposium

Mar 31, 2025, 9:00 AM EDT - 4 months ago

The Impact of the VenoValve(R) on Patients with Primary and Secondary Chronic Venous Insufficiency (CVI) to be Presented at the Society for Clinical Vascular Surgery 52nd Annual Symposium

enVVeno Medical Reports Fourth Quarter and Year-End 2024 Financial Results and Progress Towards VenoValve FDA Approval Expected in 2H25

Feb 28, 2025, 8:00 AM EST - 5 months ago

enVVeno Medical Reports Fourth Quarter and Year-End 2024 Financial Results and Progress Towards VenoValve FDA Approval Expected in 2H25

enVVeno Medical Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

Feb 19, 2025, 9:00 AM EST - 5 months ago

enVVeno Medical Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

One-Year Data from the VenoValve(R) U.S. Pivotal Trial Highlighting Impact on Patients' Quality of Life (QOL) to be Presented Today at the 37th Annual Meeting of the American Venous Forum

Feb 19, 2025, 8:45 AM EST - 5 months ago

One-Year Data from the VenoValve(R) U.S. Pivotal Trial Highlighting Impact on Patients' Quality of Life (QOL) to be Presented Today at the 37th Annual Meeting of the American Venous Forum

Interim Two-Year Follow-Up Data from the VenoValve(R) U.S. Pivotal Trial to be Presented Today at the VESS 2025 Annual Winter Meeting

Feb 7, 2025, 9:00 AM EST - 6 months ago

Interim Two-Year Follow-Up Data from the VenoValve(R) U.S. Pivotal Trial to be Presented Today at the VESS 2025 Annual Winter Meeting

enVVeno Medical Successfully Completes Final Wave of Implants in Pre-Clinical GLP Study for enVVe

Dec 16, 2024, 8:50 AM EST - 7 months ago

enVVeno Medical Successfully Completes Final Wave of Implants in Pre-Clinical GLP Study for enVVe

enVVeno Medical Highlights Successful 2024 VEITH Symposium with Launch of Recap Website

Nov 27, 2024, 8:30 AM EST - 8 months ago

enVVeno Medical Highlights Successful 2024 VEITH Symposium with Launch of Recap Website

enVVeno Medical to Present Definitive One Year Data from the VenoValve U.S. Pivotal Trial Today at the 51st Annual VEITH Symposium

Nov 20, 2024, 8:30 AM EST - 8 months ago

enVVeno Medical to Present Definitive One Year Data from the VenoValve U.S. Pivotal Trial Today at the 51st Annual VEITH Symposium

enVVeno Medical Submits the VenoValve PMA Application Seeking FDA Approval

Nov 19, 2024, 8:15 AM EST - 8 months ago

enVVeno Medical Submits the VenoValve PMA Application Seeking FDA Approval

Hancock Jaffe to Participate in the Duologue Series Virtual Webinar Hosted by Ladenburg Thalmann

Sep 24, 2021, 9:00 AM EDT - 4 years ago

Hancock Jaffe to Participate in the Duologue Series Virtual Webinar Hosted by Ladenburg Thalmann

Hancock Jaffe To Rebrand As enVVeno Medical

Sep 22, 2021, 7:09 AM EDT - 4 years ago

Hancock Jaffe To Rebrand As enVVeno Medical

Hancock Jaffe Announces Corporate Rebranding to Reflect Prioritization of its Development Pipeline on Venous Disease Programs

Sep 21, 2021, 4:00 PM EDT - 4 years ago

Hancock Jaffe Announces Corporate Rebranding to Reflect Prioritization of its Development Pipeline on Venous Disease Programs

Hancock Jaffe to Host Corporate Update Conference Call and Webcast on September 21, 2021

Sep 15, 2021, 8:05 AM EDT - 4 years ago

Hancock Jaffe to Host Corporate Update Conference Call and Webcast on September 21, 2021

Hancock Jaffe Laboratories: Developing Nature-Mimetic Bioprosthetics

Sep 8, 2021, 7:43 PM EDT - 4 years ago

Hancock Jaffe Laboratories: Developing Nature-Mimetic Bioprosthetics

Hancock Jaffe Laboratories Announces $20 Million Registered Direct Offering Priced At-the-Market Under NASDAQ Rules

Sep 7, 2021, 8:05 AM EDT - 4 years ago

Hancock Jaffe Laboratories Announces $20 Million Registered Direct Offering Priced At-the-Market Under NASDAQ Rules

Hancock Jaffe Highlights Two-Year Data For Venous Insufficiency Valve

Aug 19, 2021, 11:49 AM EDT - 4 years ago

Hancock Jaffe Highlights Two-Year Data For Venous Insufficiency Valve

Hancock Jaffe Presents New Positive Two-Year VenoValve Data at the Society for Vascular Surgery Annual Meeting

Aug 19, 2021, 8:00 AM EDT - 4 years ago

Hancock Jaffe Presents New Positive Two-Year VenoValve Data at the Society for Vascular Surgery Annual Meeting

Hancock Jaffe Stock Surges On FDA Breakthrough Designation For Its Venous Insufficiency Device

Aug 3, 2021, 8:58 AM EDT - 4 years ago

Hancock Jaffe Stock Surges On FDA Breakthrough Designation For Its Venous Insufficiency Device

FDA Grants Breakthrough Device Designation Status for Hancock Jaffe's VenoValve

Aug 3, 2021, 8:05 AM EDT - 4 years ago

FDA Grants Breakthrough Device Designation Status for Hancock Jaffe's VenoValve

Hancock Jaffe to Present at the Ladenburg Thalmann 2021 Healthcare Conference

Jul 8, 2021, 9:05 AM EDT - 4 years ago

Hancock Jaffe to Present at the Ladenburg Thalmann 2021 Healthcare Conference

Hancock Jaffe Principal Investigator Dr. Jorge Hernando Ulloa Presents VenoValve One Year First-In-Human Data at Charing Cross International Symposium

Apr 23, 2021, 12:40 PM EDT - 4 years ago

Hancock Jaffe Principal Investigator Dr. Jorge Hernando Ulloa Presents VenoValve One Year First-In-Human Data at Charing Cross International Symposium

First U.S. Patent Issues on Hancock Jaffe VenoValve

Apr 7, 2021, 1:40 PM EDT - 4 years ago

First U.S. Patent Issues on Hancock Jaffe VenoValve

Hancock Jaffe Receives IDE Approval To Begin VenoValve U.S. Pivotal Trial

Apr 5, 2021, 7:30 AM EDT - 4 years ago

Hancock Jaffe Receives IDE Approval To Begin VenoValve U.S. Pivotal Trial

Hancock Jaffe Submits IDE Application to FDA for VenoValve U.S. Pivotal Trial

Mar 8, 2021, 8:30 AM EST - 4 years ago

Hancock Jaffe Submits IDE Application to FDA for VenoValve U.S. Pivotal Trial

Hancock Jaffe Concludes Successful VenoValve Pre-IDE Meeting with FDA

Jan 12, 2021, 8:30 AM EST - 4 years ago

Hancock Jaffe Concludes Successful VenoValve Pre-IDE Meeting with FDA

Hancock Jaffe Announces Executive Promotions

Dec 30, 2020, 4:15 PM EST - 4 years ago

Hancock Jaffe Announces Executive Promotions

Hancock Jaffe Deemed Compliant With All NASDAQ Continued Listing Requirements

Dec 21, 2020, 8:30 AM EST - 4 years ago

Hancock Jaffe Deemed Compliant With All NASDAQ Continued Listing Requirements

kmx_swing
kmx_swing Jul. 26 at 8:52 AM
$NVNO not sure how high it will go...but we will reach at minimum $8 because of warrants...then is the question how long it will take market to digest that those cashed $70M are in fact an excellent news..
0 · Reply
cohunter9
cohunter9 Jul. 26 at 2:57 AM
$NVNO min 4x profit, or lose it all.
1 · Reply
LifeisaMeme
LifeisaMeme Jul. 25 at 11:52 PM
$NVNO Yea im tired of stocks going up that make no money and good companies go down. Im so fucking tired of this bullshit. The SEC needs to do something about it but of course it will never happen.
0 · Reply
Icemanja
Icemanja Jul. 25 at 11:19 PM
$NVNO Maybe if they post bad new we'll go up? At this point i've seen it all. Not sure who Breman pissed off with deep pockets but they keep hammerring us no matter what!!
1 · Reply
Thorne321
Thorne321 Jul. 25 at 8:32 PM
$NVNO I’m coming to conclusion there to quite about this prone for a buyout . Why would they not advertise this or give it more publicity. So others can acquire at relatively lower price I guess ?
0 · Reply
Liverpool13
Liverpool13 Jul. 25 at 8:03 PM
$NVNO “…”the good news is that we are working here in Irvine on a device that we are waiting for FDA approval for people with much more severe disease, called the VenoValve, which is a prosthetic valve that implanted into the vein that restores normal flow. It’s a new valve in these legs that have very diseased valves. So that’s what we are waiting for from the FDA for approval of our device” -Dr Marc Glickman, CMO. Saturday Agenda, Newsmax (end of interview posted on news section of envveno website
0 · Reply
Liverpool13
Liverpool13 Jul. 25 at 7:57 PM
$NVNO not sure if this was posted yet but more interviews of the CMO are added to the news tab of the website and BINGO!….CMO plugs the device pending FDA approval! See the Saturday Newsmax video which should be the third overall video (2nd of the Newsmax ones). He plugs device in last 30 seconds of video interview. Video in the link is entitled: “Dr. Marc Glickman, Senior Vice President and Chief Medical Officer for enVVeno Medical, joins Newsmax’s Saturday Agenda to explain President Donald Trump’s health updates announced by the White House on Thursday.” https://envveno.com/in-the-news/
0 · Reply
LifeisaMeme
LifeisaMeme Jul. 25 at 7:39 PM
$NVNO Berman literally thinks retail is stupid. We aint selling buddy. Either you go bankrupt, or we all gain from this. Contact FDA Berman. OMG your Ivy league start acting like it.
0 · Reply
The_Giggly_Hyena
The_Giggly_Hyena Jul. 25 at 6:44 PM
$NVNO
1 · Reply
kmx_swing
kmx_swing Jul. 25 at 6:42 PM
$NVNO FDA hates Trump...that is why they have not approved yet...we need Palestian leaders to have chronic venous insufficiency and Obama in charge...then the approval is guaranteed yesterday 😉🫣
1 · Reply
DegenStock
DegenStock Jul. 25 at 6:24 PM
$NVNO in BERMANS recent podcast/interview, he compared this company to INARI medical. I was invested in INARI at 45$, and they ended up being bought out by Stryker late last year (went to effect this year) for 90$ a share. Similar to NVNO, INARI had a line of different treatments for venous thromboembolism clot removal without use of thrombolytic drugs. First of a kind in its field. Like NVNO, INARI has their LimFlow System, which also received FDA breakthrough device designation. I see a lot of similarities, now the executive management just needs to execute
0 · Reply
LifeisaMeme
LifeisaMeme Jul. 25 at 5:30 PM
$NVNO MAX LIMIT BRAINCELL DAMAGE
0 · Reply
DegenStock
DegenStock Jul. 25 at 2:48 PM
$NVNO
0 · Reply
Anil501
Anil501 Jul. 25 at 2:43 PM
$NVNO
0 · Reply
DegenStock
DegenStock Jul. 25 at 2:40 PM
$NVNO anyone selling this late in the game and this close to FDA decision are trippin
1 · Reply
TW_Research
TW_Research Jul. 25 at 2:24 PM
$NVNO Newsweek article mentions the VenoValve as a possible treatment for Trump... https://www.newsweek.com/donald-trump-health-swollen-ankles-white-house-response-2100379
0 · Reply
Dinkmaster
Dinkmaster Jul. 25 at 1:38 PM
$NVNO This ceo is focused on everything, but getting the stock up. Not a good sign
1 · Reply
10baggerPete
10baggerPete Jul. 25 at 1:01 PM
$NVNO One day closer .... Sidelines is no place to be right now.
0 · Reply
topstockalerts
topstockalerts Jul. 25 at 12:12 PM
$NVNO what’s your target for today? 🍾 ....🍾
0 · Reply
kmx_swing
kmx_swing Jul. 25 at 3:50 AM
$NVNO
1 · Reply
2thGuardian
2thGuardian Jul. 25 at 3:49 AM
$NVNO
0 · Reply
cohunter9
cohunter9 Jul. 25 at 1:34 AM
$NVNO lets climb to 6-7 before FDA decision. Then 17.25
0 · Reply